AnaptysBio UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. I think we'll get started with our last fireside of the day. I'm Madeleine Lee. I'm a member of the U.S. biotech team here at UBS. I'm joined here today by Dan Faga, CEO at AnaptysBio. Dan, thanks for joining us today.
Pleasure to be here. Thank you.
Second time today. Obviously there's been a lot of change at Anaptys over the last year. You spun out the biotech operation. Maybe we could just start with, if you could just give us a quick overview of where the company stands, rationale for spinning that out, and yeah, we can start there.
Perfect. About a year or so ago, we announced the intention to spin off our biotech pharma operations from Anaptys. We successfully completed that transaction on April 20th of this year, so six, seven months ago. The transition's gone really well, and I would say it's long from complete at this point. Today's Anaptys looks very, very different than prior to the separation. We've transformed the company into a virtual organization. We have zero employees. We are contractor-based. We have a full-time CFO. I'm part-time running the company. We have a group of folks that support the finance team, keeping things afloat. It's not an overly complicated business to run, where your two core assets are two royalty threads. One for a product called Jemperli, which is sold by GSK, approved in dozens of markets as a PD-1 antagonist.
The second program is an IL-36 receptor antagonist that was out-licensed to Vanda. As time continues to creep on here, we are about a month away from the PDUFA for hopeful approval in a disease called GPP, generalized pustular psoriasis, which is a rare derm disorder. So exiting this year, hopefully we will have two different royalty threads at our commercial stage. We are running the company at a very high EBIT margin, as you can imagine, in this type of a framework, where you have 95% EBIT margins, less than $10 million yearly operating expenses. So virtual royalty-based company designed to protect and manage the royalty threads of the two assets I described.
Got it. Exciting and very, very different.
Indeed than anything else that is out there.
Yeah. Could you remind us maybe, just to be, you know, with Jemperli, how you think about the growth trajectory of the drug from here?
Just chime in. Yeah. GSK recently announced their third quarter results, and to date, Jemperli sold over $1 billion of revenue through calendar year 2026.
The drug is growing approximately 30% year-over-year. At high growth stage, fueled by a launch in endometrial cancer about two plus years ago in the U.S., and following on in Europe a year and a half ago. Then very recently, not in the Q3 numbers, we had an approval in dMMR rectal cancer, first immunotherapy approved in rectal cancer to date. I think broad growth prospects, we often cite from our company really, at least to date, how GSK is guiding around the asset. They've discussed upwards of 2 billion pounds or $2.7 billion in peak monotherapy sales tied directly to endometrial cancer and rectal cancer.
I think a lot of upside from here to go just in the commercial stage label or indications that are approved as of today. As it relates to the actual royalties we receive on those revenues, we have a pretty almost exponentially tiered royalty stream. Up to $1 billion in revenue, we receive 8% royalties. Then it triggers up to 12% to $1.5 billion of calendar year revenues, 20% up to $2.5 billion, and then 25% beyond there. In the fourth quarter, and this is what's great about the way our royalty business works, as Jemperli grows, our revenue is going to grow, again, continually on almost an exponential rate on a relative basis as you cycle through a calendar year.
Said differently, since they've already cleared $1 billion through this year, all the Q4 revenues that we ultimately will receive will be at a 12% royalty rate, or even potentially a 15% royalty rate, depending on how well GSK performs in Q4.
Got it. Could you remind us as well the anticipated loss of exclusivity, including any potential extensions? I think the language in your 10-K is until the last to expire relevant patent. I did want to touch on, I think that they recently initiated a trial of the subcu version of JEMPERLI in collaboration with Alteogen.
Would those patents covering the subcu formulation also qualify for that last to expire?
Yeah, good question. The history of Anaptys has been around for over 20 years. The assets that we're talking about, these royalties we have, were from homegrown or discovered programs over time. The origination of JEMPERLI, or the PD-1 antagonist, was from an out-licensing deal back in 2014 when it was really just a drug candidate in the earlier days of IO. When we talk about the patent life, we were obviously directly involved as a company in the composition of matter of this IP in the earlier days of common ways to think about extending IP life cycle. What's in the public domain that we recite, and this is actually in GSK's yearly filings, is a 2035 composition of matter in the U.S., 2036 in Europe, and 2037 in Japan. There is ability for extensions from that.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
